

Azvodine vs Standard Treatment for COVID-19

Author(s): Cruciani F, De Crescenzo F, Vecchi S, Saulle R, Mitrova Z, Amato L, Davoli M.

Question: Should Azvodine compared to Standard Treatment be used for COVID-19?

Setting: Inpatient

Certainty assessment							№ of patients		Effect		Certainty
№ of studies	Study design	Risk of bias	Inconsistency	Indirectness	Imprecision	Other considerations	Azvodine	Standard treatment	Relative (95% CI)	Absolute (95% CI)	
All-cause mortality											
1 ¹	randomised trials	very serious _a	not serious	not serious	very serious _b	none	No death reported				⊕○○○ VERY LOW
SARS-CoV-2 clearance											
1 ¹	randomised trials	very serious _a	not serious	not serious	very serious _b	none	10/10 (100.0%)	4/10 (40.0%)	RR 2.33 (1.13 to 4.80)	532 more per 1.000 (from 52 more to 1.000 more)	⊕○○○ VERY LOW
Number of patients with any adverse event											
1 ¹	randomised trials	very serious _a	not serious	not serious	very serious _b	none	0/10 (0.0%)	3/10 (30.0%)	RR 0.14 (0.01 to 2.45)	258 fewer per 1.000 (from 297 fewer to 435 more)	⊕○○○ VERY LOW
Number of patients with serious adverse events											
1 ¹	randomised trials	very serious _a	not serious	not serious	very serious _b	none	No serious adverse event reported				⊕○○○ VERY LOW
Time to SARS-CoV 2 clearance											
1 ¹	randomised trials	very serious _a	not serious	not serious	very serious _b	none	10	10	-	SMD 1.27 lower (2.25 lower to 0.29 lower)	⊕○○○ VERY LOW

Explanations

a. Downgraded of two levels for high risk of performance bias and unclear risk of selection, attrition and reporting bias

b. Downgraded of two levels for very small sample size

References

1. Ren Z, Luo H, Yu Z, et al. A Randomized, Open-label, Controlled Clinical Trial of Azvodine Tablets in the Treatment of Mild and Common COVID-19, A Pilot Study [published online ahead of print, 2020 Jul 14]. Adv Sci (Weinh). 2020;2001435. doi:10.1002/advs.202001435